Common Hormonal Contraceptive Linked to Risk of Rare Brain Tumor
Concerns are mounting over a potential link between a common hormonal contraceptive jab and the risk of rare brain tumors.
📍 How it ended
Reports linked a common hormonal contraceptive, including the Depo-Provera jab, to the risk of rare brain tumors. Victims called for risk warnings and updated drug guidance from NHS Scotland.
The story quieted without a definitive conclusion in the coverage.
Epilogue added 85d ago, after coverage quieted.
The obvious questions
Which contraceptive is linked to the brain tumors?
Coverage specifically identifies the Depo-Provera contraceptive jag.
What are the demands from victims in the UK?
Victims are calling for risk warnings to be provided to women and for NHS Scotland to update its drug guidance.
Which regulatory body has addressed this recently?
The European Medicines Agency (EMA) through its Pharmacovigilance Risk Assessment Committee (PRAC).
The story so far
- Velocity & Diffusion: Coverage escalated across 6 distinct news outlets with 6 published articles, achieving a live velocity of 4.
- Primary Driver: Concerns are mounting over a potential link between a common hormonal contraceptive jab and the risk of rare brain tumors.
- Predictive Outlook: Newsylist algorithmic models forecast this story will remain a dominant headline through tomorrow.
- Source Integrity: Verified strictly against primary headline reporting under zero-hallucination protocols.
Reports have emerged linking a hormonal contraceptive injection, specifically Depo-Provera, to the development of rare brain tumors. Individuals affected by inoperable tumors have spoken out, claiming they were not provided with adequate risk warnings before receiving the treatment.
Coverage from ScienceAlert, The Independent, and the New York Post emphasizes the health risks associated with the drug. In the UK, reports from Yahoo News UK and the Daily Record highlight calls for NHS Scotland to update its drug guidance to prevent further patients from being impacted.
Attention is currently on the European Medicines Agency (EMA), as recent meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) held July 6-9, 2026, address these safety concerns.
Synthesized by Newsylist from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 86d ago.
Coverage (6)
-
It’s not just Depo-Provera New York Post · 89d ago
-
-
-
-
-
Common Hormonal Contraceptive Linked to Risk of Rare Brain Tumor ScienceAlert · 89d ago broke it first
The coverage curve
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
How do you expect this trend to evolve over the next 24 hours?
Cast your vote to register reader intelligence on the velocity and trajectory of this coverage.
People, places & organizations
Topics
Related trends
A breakthrough in pancreatic cancer has experts excited
7 news sources are covering this Health story right now — Newsylist is tracking how fast it spreads.
Not all birth controls are equal, some are linked to higher risk of brain tumors, study finds
7 news sources are covering this Health story right now — Newsylist is tracking how fast it spreads.
Pancreatic cancer breakthrough has big implications for early detection effort - San Diego Union-Tribune
Experimental cancer treatment Daraxonrasib is gaining momentum as regulators fast-track review and clinical data suggests potential advancements in patient care.
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 June 2026
Eli Lilly shares surge following a CHMP recommendation for Jaypirca's EU approval to treat chronic lymphocytic leukemia.